Depending on the strength at which the doses were given, the vaccine appeared to be either 90% or 62% effective. But it did not break down how many cases were found in each group of participants — those who received the half-strength initial dose, the regular-strength initial dose and the placebo. The AstraZeneca vaccine, which uses a different approach involving a chimpanzee virus to provoke an immune response to the coronavirus, had all the hallmarks of a blockbuster. Compared to most of the other leading COVID-19 vaccine developers, AstraZeneca is inexperienced when it comes to vaccines. AstraZeneca has not been testing the promising half-strength initial dose in its ongoing US trial.

Source: bd News24 November 26, 2020 03:22 UTC